Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

3

About Seamus Mulligan

Seamus Mulligan Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Seamus Mulligan News

ONK Therapeutics Closes US$8M Financing

Oct 19, 2020

ONK Therapeutics Ltd , a Galway, Ireland-based natural killer (NK) cell therapy company, raised US$8M in financing. This round, which brought the total raised in the last six months to US$14.6M, was led by Acorn Bioventures, and current shareholders, principally Seamus Mulligan, an experienced biopharmaceutical executive. The company intends to use the funds to expand the team, its pre-clinical R&D and its manufacturing capabilities, in order to progress its novel, dual-targeted, natural killer (NK) cell therapy platform towards human clinical trials. Founded in 2015, by Chief Scientific Officer (CSO) Prof. Michael O’Dwyer, and led by newly appointed CEO Chris Nowers, ONK Therapeutics is a pre-clinical stage company dedicated to the development of a off-the-shelf, dual-targeted NK cell therapy platform, targeting solid and hematological cancers. This approach combines the expression of a chimeric antigen receptor (CAR) and a high affinity, membrane-bound TNF related apoptosis inducing ligand variant (TRAILv). This is coupled with a research focus on strategies to enhance homing and persistence as well as to overcome exhaustion, including the exploration of proprietary gene edits, such as the deletion of checkpoint inhibitory receptors in NK cells. The company is advancing an expanding portfolio of product candidates based on this platform. The company’s lead research program, ONKT101, is a dual-targeted NK cell therapy incorporating a CD19 CAR and TRAILv targeting the death receptor pathway (DR5) intended for the treatment of relapsed/refractory B cell malignancies. This program is partnered with Avectas and will utilize its proprietary SOLUPORETM technology as a means of non-viral genetic modification. The second program, ONKT102, combines an optimized affinity CD38 CAR and a TRAILv targeting DR5 intended for the treatment of patients with relapsed/refractory multiple myeloma. Nowers is an experienced biopharma executive, with significant cell therapy expertise from his tenure at both Kite Pharma (Head of Europe) and Cell Medica (CEO). Additional roles spanning more than 25 years in the biopharma industry include senior leadership positions as CEO of Avantogen Oncology, General Management roles at Amgen, and senior global and regional commercial leadership roles in the field of immunology at Bristol-Myers Squibb (BMS). Following the investment, Isaac Manke, PhD, Partner at Acorn Bioventures, and Mr Nowers will join the board of directors. FinSMEs

Seamus Mulligan Investments

3 Investments

Seamus Mulligan has made 3 investments. Their latest investment was in ONK Therapeutics as part of their Series A on October 10, 2020.

CBI Logo

Seamus Mulligan Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/19/2020

Series A

ONK Therapeutics

$8M

Yes

4

4/16/2020

Series C

Subscribe to see more

$99M

Subscribe to see more

10

4/9/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/19/2020

4/16/2020

4/9/2019

Round

Series A

Series C

Series B

Company

ONK Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$8M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.